| Revue: | Salud mental |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000362422 |
| ISSN: | 0185-3325 |
| Autores: | Apiquian, Rogelio1 Córdoba, Rodrigo2 Louza, Mario3 Fresán, Ana4 |
| Instituciones: | 1Universidad de las Américas, División de Ciencias del Comportamiento y del Desarrollo, México, Distrito Federal. México 2Centro de Investigación del Sistema Nervioso, Bogotá. Colombia 3Universidade de Sao Paulo, Faculdade de Medicina, Sao Paulo. Brasil 4Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Subdirección de Investigaciones Clínicas, México, Distrito Federal. México |
| Año: | 2013 |
| Periodo: | Ene-Feb |
| Volumen: | 36 |
| Número: | 1 |
| Paginación: | 19-26 |
| País: | México |
| Idioma: | Español |
| Tipo de documento: | Estadística o encuesta |
| Enfoque: | Caso clínico |
| Resumen en español | sistema de salud |
| Resumen en inglés | Schizophrenia is a chronic psychiatric disorder associated to high healthcare costs mainly driven by inpatient care. Lack of adherence to antipsychotic treatment is a common reason for relapse and rehospitalization leading to poor prognosis and global functional impairment of patients. Risperidone long-acting injection (RLAI) has demonstrated its efficacy in treating symptoms of schizophrenia and offers the potential to improve adherence to treatment. Objective To determine clinical and functional efficacy of RLAI and use of health resources (eg., hospitalizations) in a 2-year follow up study among patients with schizophrenia from Latin America. Method The electronic Schizophrenia Treatment Adherence Registry (e-STAR) is an observational study of patients who start treatment with RLAI. Data from patients recruited in Mexico, Colombia and Brazil were collected retrospectively for one year prior to baseline, at baseline and every three months for 24 months. Hospitalization rates and treatment regime were registered. Efficacy was assessed using the Clinical Global Impression of Illness-Severity Scale (CGI-S), while the Global Assessment of Functioning (GAF) and the Personal and Social Performance (PSP) were used for the evaluation of functioning. Results Seventy-three patients completed the two-year follow-up. The proportion of patients hospitalized declined from 16.4% before treatment to 4.1% after 2 years of treatment with RLAI. Only 2.7% discontinued the treatment due to lack of efficacy. Significant improvements were reported in illness severity as well as in global functioning assessed by the CGI-S, GAF and PSP scales, respectively. Discussion Our results give further support of the efficacy of RLAI for the treatment of schizophrenia. Additional to symptom severity reduction and functional recovery, improved treatment adherence and reduced hospitalization rates were observed with the use of RLAI. In a real world clinical setting. RLAI offers an.. |
| Disciplinas: | Medicina |
| Palabras clave: | Farmacología, Psiquiatría, Terapéutica y rehabilitación, Esquizofrenia, Risperidona, Liberación prolongada, Adherencia al tratamiento, Seguimiento, Hospitalización |
| Keyword: | Medicine, Pharmacology, Psychiatry, Therapeutics and rehabilitation, Schizophrenia, Risperidone, Prolonged release, Treatment adherence, Follow up, Hospitalization |
| Texte intégral: | Texto completo (Ver HTML) |
